journal article·2018-07-04Open access

Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment

Sania Naz, Hira Shahzad, Attarad Ali, Muhammad Zia

Abstract

Breast cancer is a group of diseases with various subtypes and leads to high mortality throughout the globe. Various conventional techniques are in practice to cure breast cancer but these techniques are linked with various shortcomings. Mostly these treatments are not site directed and cause toxicity towards normal cells. In order to overcome these issues, we need smart system that can deliver anticancer drugs to specific sites. Targeted drug delivery can be achieved via passive or active drug delivery using nanocarriers. This mode of drug delivery is more effective against breast cancer and may help in the reduction of mortality rate. Potentially used nanocarriers for targeted drug delivery belong to organic and inorganic molecules. Various FDA approved nano products are in use to cure breast cancer. However, body's defense system is main limitation for potential use of nano systems. However, this can be overcome by surface modification of nanocarriers. In this review, breast cancer and its types, targeted drug delivery and nanocarriers used to cure breast cancer are discussed. By progressing nanotechnology, we will be able to fight against this life threatening issue and serve the humanity, which is the basic aim of scientific knowledge.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan;

Institute of Biochemistry and Biotechnology, PMAS Arid Agriculture, Rawalpindi, Pakistan

References (100+)

Show source-provided references
1. Bhandare N · J Nuclear Med Rad Ther · 2014 · 5 · 195
2. 10.1016/j.drudis.2012.05.01010.1016/j.drudis.2012.05.010 ↗
3. 10.3322/caac.2010710.3322/caac.20107 ↗
4. 10.1016/j.drudis.2010.08.00610.1016/j.drudis.2010.08.006 ↗
5. 10.1200/JCO.2004.08.18110.1200/JCO.2004.08.181 ↗
6. 10.1038/nrclinonc.2009.16610.1038/nrclinonc.2009.166 ↗
7. 10.1002/em.1006210.1002/em.10062 ↗
8. 10.1038/nnano.2012.16710.1038/nnano.2012.167 ↗
9. 10.1002/cncr.2031210.1002/cncr.20312 ↗
10. Vance GH · Arc Pathol Lab Med · 2009 · 133 · 61110.5858/133.4.611 ↗
11. 10.1007/s10544-008-9209-010.1007/s10544-008-9209-0 ↗
12. 10.6004/jnccn.2011.001610.6004/jnccn.2011.0016 ↗
13. 10.1016/S0140-6736(09)60316-010.1016/S0140-6736(09)60316-0 ↗
14. 10.1002/cncr.2383610.1002/cncr.23836 ↗
15. 10.1056/NEJMoa110965310.1056/NEJMoa1109653 ↗
16. 10.2165/00003495-200767090-0000610.2165/00003495-200767090-00006 ↗
17. 10.1158/0008-5472.CAN-08-384510.1158/0008-5472.CAN-08-3845 ↗
18. 10.1093/jnci/djn32410.1093/jnci/djn324 ↗
19. 10.1038/sj.embor.740070510.1038/sj.embor.7400705 ↗
20. 10.1006/gyno.2000.600310.1006/gyno.2000.6003 ↗
21. 10.1038/nrc156610.1038/nrc1566 ↗
22. 10.1016/j.drup.2011.01.00310.1016/j.drup.2011.01.003 ↗
23. 10.1002/jso.2169810.1002/jso.21698 ↗
24. 10.1158/1078-0432.CCR-11-293810.1158/1078-0432.CCR-11-2938 ↗
25. 10.1158/0008-5472.CAN-08-469810.1158/0008-5472.CAN-08-4698 ↗
26. 10.1021/bc500545z10.1021/bc500545z ↗
27. 10.1146/annurev.bioeng.9.060906.15202510.1146/annurev.bioeng.9.060906.152025 ↗
28. 10.1016/j.jconrel.2012.07.01010.1016/j.jconrel.2012.07.010 ↗
29. 10.1016/j.addr.2012.11.00610.1016/j.addr.2012.11.006 ↗
30. 10.1038/nmat377610.1038/nmat3776 ↗
31. 10.1016/j.addr.2014.01.00710.1016/j.addr.2014.01.007 ↗
32. 10.1016/j.nano.2005.06.00410.1016/j.nano.2005.06.004 ↗
33. 10.4172/2157-7439.1000103e10.4172/2157-7439.1000103e ↗
34. 10.1016/j.autrev.2014.10.00210.1016/j.autrev.2014.10.002 ↗
35. 10.1016/j.biomaterials.2012.10.01310.1016/j.biomaterials.2012.10.013 ↗
36. 10.1038/onc.2014.28210.1038/onc.2014.282 ↗
37. 10.1002/anie.20140026810.1002/anie.201400268 ↗
38. 10.1016/j.eurpolymj.2015.01.01610.1016/j.eurpolymj.2015.01.016 ↗
39. 10.1021/nl050127s10.1021/nl050127s ↗
40. 10.1158/1535-7163.MCT-06-014110.1158/1535-7163.MCT-06-0141 ↗
41. 10.1021/ar800150g10.1021/ar800150g ↗
42. 10.1007/s00216-005-0247-710.1007/s00216-005-0247-7 ↗
43. 10.1166/jbn.2016.221410.1166/jbn.2016.2214 ↗
44. 10.1007/s13277-015-4519-310.1007/s13277-015-4519-3 ↗
45. 10.18632/oncotarget.801210.18632/oncotarget.8012 ↗
46. 10.1158/0008-5472.CAN-15-128610.1158/0008-5472.CAN-15-1286 ↗
47. 10.3109/1061186X.2012.71213010.3109/1061186X.2012.712130 ↗
48. 10.1016/S0140-6736(97)11423-410.1016/S0140-6736(97)11423-4 ↗
49. 10.1200/JCO.2013.54.225810.1200/JCO.2013.54.2258 ↗
50. Yuzhakova DV · Med Technol Med · 2016 · 8 · 173
51. 10.1146/annurev-med-040210-16254410.1146/annurev-med-040210-162544 ↗
52. 10.1002/cncr.2203510.1002/cncr.22035 ↗
53. 10.1007/s10856-010-3998-410.1007/s10856-010-3998-4 ↗
54. Conde J · J Drug Deliv · 2011 · 2012 · 1
55. Jannesari M · Int J Nanomed · 2011 · 993
56. 10.2217/nnm.11.3010.2217/nnm.11.30 ↗
57. New RRC. · 1990
58. 10.1038/nrd163210.1038/nrd1632 ↗
59. 10.1016/j.nano.2008.06.00210.1016/j.nano.2008.06.002 ↗
60. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
61. 10.1016/0009-3084(93)90071-A10.1016/0009-3084(93)90071-A ↗
62. 10.1097/01.cad.0000167902.53039.5a10.1097/01.cad.0000167902.53039.5a ↗
63. 10.2165/00003088-200342050-0000210.2165/00003088-200342050-00002 ↗
64. 10.1016/j.ejpb.2004.06.00910.1016/j.ejpb.2004.06.009 ↗
65. 10.1016/j.ijpharm.2009.12.06110.1016/j.ijpharm.2009.12.061 ↗
66. 10.1007/s00280-003-0719-410.1007/s00280-003-0719-4 ↗
67. 10.1016/j.jconrel.2008.06.00410.1016/j.jconrel.2008.06.004 ↗
68. 10.1016/j.chemphyslip.2009.08.00310.1016/j.chemphyslip.2009.08.003 ↗
69. 10.1021/la903867a10.1021/la903867a ↗
70. 10.1016/j.jconrel.2009.10.00210.1016/j.jconrel.2009.10.002 ↗
71. 10.1021/ja805046910.1021/ja8050469 ↗
72. 10.1016/j.ejpb.2008.09.02610.1016/j.ejpb.2008.09.026 ↗
73. 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
74. 10.4143/crt.2009.41.1.110.4143/crt.2009.41.1.1 ↗
75. 10.1007/s11095-008-9800-310.1007/s11095-008-9800-3 ↗
76. 10.1016/j.ijpharm.2009.10.01810.1016/j.ijpharm.2009.10.018 ↗
77. 10.1038/263797a010.1038/263797a0 ↗
78. 10.1002/jps.260068121510.1002/jps.2600681215 ↗
79. 10.1126/science.812824510.1126/science.8128245 ↗
80. 10.1016/S0927-7765(99)00156-310.1016/S0927-7765(99)00156-3 ↗
81. Tanford C. · 1991
82. 10.1038/sj.clpt.610040010.1038/sj.clpt.6100400 ↗
83. 10.1158/0008-5472.CAN-04-255010.1158/0008-5472.CAN-04-2550 ↗
84. 10.1073/pnas.071171410510.1073/pnas.0711714105 ↗
85. 10.2165/00003088-200847100-0000110.2165/00003088-200847100-00001 ↗
86. 10.1007/s11095-010-0233-410.1007/s11095-010-0233-4 ↗
87. 10.2174/138945004334540710.2174/1389450043345407 ↗
88. 10.1023/A:102039862460210.1023/A:1020398624602 ↗
89. 10.1002/anie.20030060210.1002/anie.200300602 ↗
90. 10.1039/b309043b10.1039/b309043b ↗
91. 10.1038/nbt117110.1038/nbt1171 ↗
92. Peer D · Nat Biotechnol · 2007 · 2 · 751
93. 10.1016/j.drudis.2010.01.00910.1016/j.drudis.2010.01.009 ↗
94. 10.1021/bm700820310.1021/bm7008203 ↗
95. 10.1002/jps.2115510.1002/jps.21155 ↗
96. 10.1080/1061186040001065510.1080/10611860400010655 ↗
97. Tripathi PK · Pharmazie · 2002 · 57 · 261
98. 10.1016/j.jconrel.2004.06.00910.1016/j.jconrel.2004.06.009 ↗
99. 10.1211/jpp.60.6.000110.1211/jpp.60.6.0001 ↗
100. 10.1021/mp800022a10.1021/mp800022a ↗